Clinical Trial

Xeltis Coronary Artery Bypass Graft (XABG) First in Human (FIH)

Study acronym: XABG FIH
Enrolling by Invitation
View on ClinicalTrials.gov →
Summary
A prospective, single arm, non-randomized FIH feasibility study to evaluate the preliminary safety and performance of the XABG technology in patients with multi-vessel atherosclerotic coronary artery disease, scheduled by the local Heart Team to undergo elective coronary artery bypass (CABG) surgery.
Protocol Amendment History 2 changes
notable Primary completion pushed: 2026-03-15 -> 2027-02 2026-07-30
minor Completion pushed: 2031-02-15 -> 2031-12 2026-07-30
Trial Details
NCT Number NCT04545112
Lead Sponsor Xeltis
Conditions Multi Vessel Coronary Artery Disease
Enrollment 20 participants
Start Date 2020-10-22
Primary Completion 2027-02 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2026-07-29